Fidelity Investments
FBRX

Fidelity Investments’s Forte Biosciences FBRX Stock Holding History

Fidelity Investments’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Buy
502,826
+162,131
+48% +$3.84M ﹤0.01% 2100
2026
Q1 		$8.82M Buy
340,695
+29,730
+10% +$856K ﹤0.01% 2089
2025
Q4 		$8.48M Buy
310,965
+66,565
+27% +$1.17M ﹤0.01% 2089
2025
Q3 		$3.67M Buy
+244,400
New +$2.81M ﹤0.01% 2337
2024
Q3 		– Sell
-5
Closed -$69 – 5563
2024
Q2 		$69 Buy
+5
New +$81 ﹤0.01% 5008
2022
Q3 		– Sell
-24
Closed -$1K – 5024
2022
Q2 		$1K Buy
24
+11
+85% +$349 ﹤0.01% 4707
2022
Q1 		$0 Buy
+13
New +$492 ﹤0.01% 5126
2018
Q4 		– Sell
-941
Closed -$5.5M – 3679
2018
Q3 		$5.5M Sell
941
-424
-31% -$1.61M ﹤0.01% 2125
2018
Q2 		$4.78M Sell
1,365
-735
-35% -$2.69M ﹤0.01% 2164
2018
Q1 		$9.33M Sell
2,100
-19
-0.9% -$88K ﹤0.01% 1979
2017
Q4 		$8.15M Buy
2,119
+53
+3% +$212K ﹤0.01% 2011
2017
Q3 		$9.65M Sell
2,066
-67
-3% -$298K ﹤0.01% 1948
2017
Q2 		$9.62M Buy
+2,133
New +$12M ﹤0.01% 1958

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Fidelity Investments's FBRX Position: Q2 2026 in Review

Fidelity Investments increased its Forte Biosciences (FBRX) stake by 48% in Q2 2026, buying an estimated $3.84M and bringing the position to 502,826 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2100.

Fidelity Investments first reported a position in FBRX in Q2 2017 and has held it in 13 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Fidelity Investments held 502,826 shares of Forte Biosciences worth $10.7M as of Q2 2026.
  • Fidelity Investments bought 162,131 Forte Biosciences shares in Q2 2026, an estimated $3.84M.
  • Forte Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2100 holding.
  • Fidelity Investments first reported a position in Forte Biosciences in Q2 2017 and has held it in 13 quarters since.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.